Both pharmacological options (e.g., GLP-1 receptor agonists such as semaglutide for patients with increased appetite and delayed satiety; bupropion for individuals with emotional eating or stress-related overeating) and bariatric surgery may play important roles, depending on patients’ obesity phenotype [15]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.